AstraZeneca to showcase leadership in treating type-2 diabetes and cardiorenal complications at ADA 2020

Exploratory analysis from Farxiga DAPA-HF Phase III trial will provide insights on the onset of type-2 diabetes in heart failure patients

Sub-analysis from the DECLARE Phase III trial to highlight Farxiga’s effect on fast renal decline

AstraZeneca will present new data from the landmark Phase III DAPA-HF and DECLARE-TIMI 58 trials at the upcoming 80th American Diabetes Association (ADA) Virtual Scientific Sessions, 12-16 June 2020. The data are among 23 accepted abstracts, including four oral presentations, covering trials that showcase the depth and breadth of potential cardio, renal and metabolic benefits for patients across AstraZeneca’s portfolio.

Highlights include:

·       An oral presentation of data from the DAPA-HF trial showing the effect of Farxiga (dapagliflozin) on the incidence of new onset of type-2 diabetes (T2D) in patients with heart failure and reduced ejection fraction (HFrEF) (Abstract #271-OR)1

·       New sub analysis from the DECLARE-TIMI 58 trial, presented orally, providing insights on Farxiga’s effect on fast kidney function decline in T2D patients with established or increased risk for cardiovascular disease (Abstract #303-OR)2

·       An analysis of the DAPA-HF trial examining if background T2D therapy impacts the benefits of Farxiga in heart failure (HF) (Abstract #1112-P)3

·       A new analysis of the global observational DISCOVER real world evidence study, presented orally, reporting health-related quality of life factors in patients with T2D initiating a 2nd-line glucose-lowering therapy (Abstract #40-OR)4

·       An oral presentation of new Phase II data on investigational cotadutide, a dual receptor agonist with balanced GLP-1 and glucagon activity, showing positive effect on blood glucose levels and changes in liver fat and glycogen stores in patients with T2D (Abstract #354-OR)5

·       Brilinta (ticagrelor) data on duration of T2D, baseline HbA1c levels as well as the impact of blood sugar-lowering background therapies on outcomes in T2D patients with coronary artery disease (THEMIS diabetes subgroup) (Abstract #403-P)6

Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said: “An overwhelming majority of people with type-2 diabetes also have at least one other cardiovascular, renal or metabolic disease. The breadth and depth of data we are presenting at ADA 2020 demonstrates our commitment to developing treatment options for patients living with diabetes that go beyond glycaemic control to also protect the heart, liver and kidneys.”

In addition to its robust clinical data, AstraZeneca will also present results from a global survey of more than 1,600 physicians in 18 countries examining primary care approaches and clinical inertia in the treatment of patients with T2D.

Key abstracts and other notable abstracts to be presented at ADA:

Lead author

Abstract title

Presentation details

Cotadutide

Robertson, D.

Cotadutide (MEDI0382), a Dual Receptor Agonist With Glucagon-like Peptide-1 and Glucagon Activity, Modulates Hepatic Glycogen and Fat Content

Oral Presentation

Monday, 15 June

17:30 – 17:45

#354-OR

Robertson, D.

Cotadutide (MEDI0382), A Dual Receptor Agonist With Glucagon-like Peptide-1 And Glucagon Activity, Is Well-tolerated (<600 μG) With Robust Effects On Blood Glucose In Patients With T2DM

Poster Presentation

Saturday, 13 June

10:00 – 11:00

#951-P

Laker, R.C.

Cotadutide, a GLP-1/Gcg Receptor Co-agonist Improves Insulin Sensitivity and Restores Normal Insulin Secretory Capacity in DIO Mice

Poster Presentation

Saturday, 13 June

10:00 – 11:00     

#1800-P

Farxiga

Inzucchi, SE.

Effect of Dapagliflozin on the Incidence Of Diabetes: A Prespecified Exploratory Analysis From DAPA-HF

Oral Presentation

Monday, 15 June

8:00 – 8:15

#271-OR

Raz, I.

Effect of Dapagliflozin on Risk for Fast Decline in eGFR: Analyses from the DECLARE-TIMI 58 Trial

Oral Presentation

Monday, 15 June

14:30 – 14:45

#303-OR

Cahn, A.

Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents Analyses from DECLARE-TIMI 58

Poster Presentation

Saturday, 13 June

10:00 – 11:00

#1101-P

Ang, L.

Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients with Type 2 Diabetes

Poster Presentation

Saturday, 13 June

10:00 – 11:00

#554-P

Ono, S.

Effects of Long-term Dapagliflozin Treatment on Hemorheology (D-PATH Study)

Poster Presentation

Saturday, 13 June

10:00 – 11:00

#1106-P

Docherty, KF.

Does Background T2D Therapy Modify the Benefits of Dapagliflozin in Heart Failure? Analysis of the DAPA-HF Trial

Poster Presentation

Saturday, 13 June

10:00 – 11:00

#1112-P

Sato, D.

Dapagliflozin Suppresses Adipose Fatty Acid Accumulation in Rats Fed on High-Fat Diet but not on Normal Chow

Poster Presentation

Saturday, 13 June
10:00 – 11:00

#1946-P

Faerch, K.

Changes in Plasma Levels of Liver Enzymes in Response to Dapagliflozin, Metformin or Exercise in People with Prediabetes: The PRE-D Trial

Poster Presentation

Saturday, 13 June

10:00 – 11:00

#845-P

Clemmensen, KKB.

Effects Of Dapagliflozin, Metformin Or Exercise On Plasma Glucagon Concentrations in Individuals With Prediabetes: The PRE-D Trial

Poster Presentation

Saturday, 13 June

10:00 – 11:00

#844-P

Kabir, M.

Dapagliflozin Promotes Adipose Beiging and Lipolysis and Reduces Adipocyte Size in the Obese Prediabetic Dog

Poster Presentation

Saturday, 13 June

10:00 – 11:00

#1711-P

Brunton, S.  

Approaches to and Inertia in Cardiovascular and Renal Risk Management of Type 2 Diabetes Patients in Primary Care: Global Quantitative Survey Results

Poster Presentation

Saturday, 13 June

10:00 – 11:00

#1188-P

 

DISCOVER

Bonnet, F.

HbA1c < 7.0% 6 Months after Initiation of Second-Line Therapy in Patients with Uncontrolled Type 2 Diabetes is Associated with Good Glycemic Control at 3 Years: The DISCOVER Study

Poster Presentation

Saturday, 13 June

10:00 – 11:00

#1598-P

Nicolucci, A.

Quality of Life in People with Type 2 Diabetes Following Initiation of Second-Line Therapy: DISCOVER

Oral Presentation

Friday, 12 June

18:00 – 18:15

#40-OR

Khunti, K.

Effects of Second-Line Metformin Combination Therapies on Weight, HbA1c, and Risk of Hypoglycemia over 3 Years: The DISCOVER Study

Poster Presentation

Saturday, 13 June

10:00 – 11:00

#1590-P

Bydureon

Clegg, LE.

Once-Weekly Exenatide Effects on eGFR Slope and UACR as a Function of Baseline UACR: An EXSCEL Trial Post Hoc Analysis

Poster Presentation

Saturday, 13 June

10:00 – 11:00

#958-P

Brilinta

Leiter, LA.

Impact of Diabetes-Related Factors And Background Antihyperglycemic Therapy On The Efficacy And Safety Of Ticagrelor Added To Aspirin: Insights From The THEMIS Trial

Poster Presentation

Saturday, 13 June

10:00 – 11:00

#403-P

Early Research & Development

Mather, K.

A Direct AMPK Activator Reduces Liver Steatosis in a Mouse Model of NASH

Poster Presentation

Saturday, 13 June

10:00 – 11:00

#1820-P

Cheng, W.

Synergetic and Distinct Roles in the Control of Food Intake and Energy Balance for Subpopulations of NTS Neurons

Late-Breaking Poster Presentation

Saturday, 13 June

10:00 – 11:00

#196-LB

Gray, SM.

Discrepancy between Single-Cell RNA Sequencing and Protein Expression Assessments of GLP-1Rr Heterogeneity in Beta Cells

Poster Presentation

Saturday, 13 June

10:00 – 11:00

#2113-P

Gray, SM.

Quantification of GLP-1R Trafficking in Primary Beta Cells in Response to Different Ligands

Poster Presentation

Saturday, 13 June

10:00 – 11:00

#2114-P

AstraZeneca in CVRM

Cardiovascular, Renal and Metabolism (CVRM) together forms one of AstraZeneca’s three therapy areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling co-morbidities. The Company’s ambition is to modify or halt the natural course of CVRM diseases and potentially regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and cardiovascular health for millions of patients worldwide.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

References

1.      Inzucchi SE et al. Effect of Dapagliflozin on the Incidence Of Diabetes: A Prespecified Exploratory Analysis From DAPA-HF. Presented at: 80th American Diabetes Association Virtual Scientific Sessions, 2020 June 12-16.

2.      Raz I et al. Effect of Dapagliflozin on Risk for Fast Decline in eGFR: Analyses from the DECLARE-TIMI 58 Trial. Presented at: 80th American Diabetes Association Virtual Scientific Sessions, 2020 June 12-16.

3.      Docherty KF et al. Does Background T2D Therapy Modify the Benefits of Dapagliflozin in Heart Failure? Analysis of the DAPA-HF Trial. Presented at: 80th American Diabetes Association Virtual Scientific Sessions, 2020 June 12-16.

4.      Nicolucci A et al. Quality of Life in People with Type 2 Diabetes Following Initiation of Second-Line Therapy: DISCOVER. Presented at: 80th American Diabetes Association Virtual Scientific Sessions, 2020 June 12-16.

5.      Robertson D et al. Cotadutide (MEDI0382), a Dual Receptor Agonist With Glucagon-like Peptide-1 and Glucagon Activity, Modulates Hepatic Glycogen and Fat Content. Presented at: 80th American Diabetes Association Virtual Scientific Sessions, 2020 June 12-16.

6.      Leiter La et al. Impact of Diabetes-Related Factors And Background Antihyperglycemic Therapy On The Efficacy And Safety Of Ticagrelor Added To Aspirin: Insights From The THEMIS Trial. Presented at: 80th American Diabetes Association Virtual Scientific Sessions, 2020 June 12-16.

7.      Arnold SV et al. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. Diabetes Obes Metab 2018; 20(8):2000–3.

tags

  • Diabetes